title: [Clinical effectiveness of N-oleyl-phosphatidyl-ethanolamine (NOPE) in obesity: our experience].
abstract: Adjustment and maintenance of body weight are the result of many process combination, that affect both the gastrointestinal system and other mechanisms in the central nervous system. Often a diet modification alone is not sufficient to guarantee significant changes in body weight. For this reason, it sometimes necessary to make other interventions, in order to help an individual to adhere to the diet as much as possible and to achieve the objectives established. The N-oleyl-phosphatidyl-ethanolamine (NOPE) is a phospholipid. It can be endogenous or exogenous, and it is present in cell membranes and in much of the food. Food intake increases its production; in fact, because of certain stimuli, it is sometimes produced by the epithelial intestine cells too. Another substance whose activity is comparable to NOPE is the epigallocatechin gallate (EGCG), an abundant catechin present in the green tea, which allows a lipid lowering and antioxidant action, and acts on energy consumption as well. The aim of our study was to evaluate the effectiveness of NOPE and EGCG pharmaceutical formulation in a population of obese women, administering the supplement twice daily before meals, for a period of 60 days. The comparison between the effectiveness of the results in a homogeneous group of patients treated with diet and placebo, allows to confirm the data reported in the literature regarding the effectiveness of the pharmaceutical formulation and the absence of side effects.
authors.affiliation: Istituto di Patologia Ostetrica e Ginecologica, Università degli Studi di Catania, Catania, Italia.
authors.forename: L
authors.initials: L
authors.lastname: Ciotta
authors.forename: M
authors.initials: M
authors.lastname: Stracquadanio
authors.forename: C
authors.initials: C
authors.lastname: Formuso
authors.forename: S
authors.initials: S
authors.lastname: Di Leo
authors.forename: A
authors.initials: A
authors.lastname: Andò
authors.forename: I
authors.initials: I
authors.lastname: Pagano
mesh_terms: D000328:Adult; D000975:Antioxidants / Q000627:therapeutic use*; D001067:Appetite Depressants / Q000627:therapeutic use*; D015992:Body Mass Index; D002392:Catechin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D009767:Obesity, Morbid / Q000188:drug therapy*; D010714:Phosphatidylethanolamines / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000975:Antioxidants; D001067:Appetite Depressants; C541208:N-oleyl-phosphatidylethanolamine; D010714:Phosphatidylethanolamines; D002392:Catechin; C045651:epigallocatechin gallate